Your session is about to expire
← Back to Search
Rapamune for Cognitive Impairment (CARPE_DIEM Trial)
CARPE_DIEM Trial Summary
This trial will evaluate if Rapamune can penetrate the central nervous system and if it is safe and tolerable for older adults with MCI or early AD.
CARPE_DIEM Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2014 Phase 1 & 2 trial • 30 Patients • NCT00286156CARPE_DIEM Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You currently use tobacco, illegal drugs, or drink alcohol excessively.You are taking blood-thinning medications other than aspirin.You are taking medications that can affect the way your body processes other drugs.You have diabetes with high HbA1c levels or are taking medication for diabetes.You have had skin ulcers or problems with healing wounds in the past.Your blood cell counts are within the normal range and have not shown any significant changes.You currently have liver disease or any known liver or bile duct problems.You have taken medication that weakens your immune system in the past year.You have received chemotherapy or radiation treatment in the past year.You have a current or ongoing lung disease or low oxygen levels in your blood.You have long-term heart failure.You had a heart attack, heart disease, stroke, or other serious heart or intestinal problems in the last 6 months.You have a major neurological condition other than Alzheimer's disease.Your blood pressure is not well controlled and is consistently too high.You have a current health condition like inflammation, infection, or mental illness that is not well controlled.You have had a brain scan that showed a growth or other issue that would make it unsafe for you to have a spinal tap.You have been diagnosed with mild cognitive impairment or have certain memory test results that show impairment, as confirmed by a clinician.
- Group 1: RAPA intervention
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there precedents of Rapamune use in prior research studies?
"Presently, there are 125 active Rapamune trials with 13 at Phase 3. Despite the majority of studies being administered in Cincinnati, Ohio, this medication is accessible through 1074 medical facilities around the world."
What is the aggregate amount of individuals participating in this research?
"Unfortunately, this clinical trial is not taking new recruits at the moment. Initially advertised on June 1st 2020 and last modified February 3rd 2022 - if you're in search of another study, there are 982 trials actively enrolling Alzheimer's disease patients and 125 recruiting participants for Rapamune."
Could I be accepted to participate in this experiment?
"To be eligible for this experiment, individuals must suffer from Alzheimer's disease and fall between the ages of 55 to 85. The trial is in search of 10 participants total."
In what ways has Rapamune been found to be beneficial?
"To prevent organ rejection, Rapamune may be prescribed for liver transplant patients and those suffering from kidney disease or renal angiomyolipomas."
Are participants of the trial restricted to those under thirty years of age?
"This clinical trial requires individuals of ages 55 to 85. In comparison, there are 98 trials available for people under 18 and 1033 specifically designed for those above the age of 65."
Is there still room in this trial for new participants?
"Clinicaltrials.gov reveals that this study is no longer actively seeking participants, as it was posted on June 1st 2020 and most recently updated on March 2nd 2022. However, 1107 other medical trials are presently looking for patients to enroll in them."
Share this study with friends
Copy Link
Messenger